Table 1 Characteristics of patients with pelvic cancer enrolled in the pilot study (n = 40)
Clinical data |  | All (n = 40) | Prostate (n = 32) | Cervix (n = 8) |
|---|---|---|---|---|
Age, median | Years (range) | 68 (36–76) | 69 (54–76) | 67 (36–75) |
ECOG/WHO PS | 0 | 33 (83%) | 27 (84%) | 6 (75%) |
1 | 6 (15%) | 4 (13%) | 2 (25%) | |
2 | 1 (2%) | 1 (3%) | 0 | |
Prostate risk group | Low risk |  | 1 (3%) | – |
Intermediate risk |  | 10 (31%) | – | |
High Risk |  | 21 (66%) | – | |
FIGO staging, cervical cancer | I |  | – | 1 (13%) |
II |  | – | 5 (62%) | |
III |  | – | 2 (25%) | |
Radiotherapy dose (Gy) /fractions | 78/39 | 17 (42%) | 17 (53%) | 0 |
62/21 | 1 (3%) | 1 (3%) | 0 | |
60/20 | 14 (35%) | 14 (44%) | 0 | |
55/25 | 2 (5%) | 0 | 2 (25%) | |
50/25 | 2 (5%) | 0 | 2 (25%) | |
46/26 | 1 (3%) | 0 | 1 (12%) | |
45/25 | 3 (7%) | 0 | 3 (38%) | |
Online MRgRT | Yes | 13 (33%) | 13 (41%) | 0 |
Brachytherapy (PDR-BT) | Yes |  | – | 6 (75%) |
Concomitant systemic treatment | Yes | 30 (75%) | 26 (81%) | 4 (50%) |